17 November 2015 - The Transparency Commission wiill consider submission for the following medicines: Jinarc (tolvaptan), Otezla (apremilast), Menotrophine (human menopausal gonadotrophin, HMG) and Eperzan (albiglutide).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2015-10/odj_ct_04112015_internet.pdf [French]